Baxter raises full-year profit forecast on robust demand for medical devices
Aug 6 (Reuters) -Baxter International BAX.N on Tuesday raised its annual profit expectations and beat Wall Street estimates for second-quarter profit on strong sales of its medical devices, driven by robust demand for medical care among patients.
Shares of the company rose 3% to $35.69 in premarket trading.
Medical device makers have been benefiting from increased demand for non-urgent surgeries such as hip and knee replacements over the past few quarters especially among older adults, who deferred these procedures during the pandemic.
Larger peers Stryker SYK.N and Boston Scientific BSX.N also raised their annual profit expectations last month, driven by demand for their medical and surgical devices.
Baxter now expects full-year adjusted profit between $2.93 and $3.01 per share, compared with its previous view of $2.88 to $2.98 per share. Analysts estimated $2.92 per share, according to LSEG data.
Revenue for the second-quarter ended June 30 came in at $3.81 billion, beating estimates of $3.76 billion.
Baxter's kidney care unit, which sells dialysis products, recorded sales of $1.12 billion for the reported quarter, compared with estimates of $1.14 billion.
The company said on Tuesday that it plans to separate the kidney care unit in late 2024 or early 2025. It had initially announced the spin-off plans last year amid supply-chain challenges and weak demand for dialysis operations.
Private equity firm Carlyle Group is in exclusive talks to acquire the kidney care unit for more than $4 billion, including debt, Reuters reported last month, citing a person familiar with the matter.
On an adjusted basis, the company earned 68 cents per share in the April-to-June quarter, compared with estimates of 66 cents per share.
Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
